245 related articles for article (PubMed ID: 25450340)
1. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives.
Roger S; Jelassi B; Couillin I; Pelegrin P; Besson P; Jiang LH
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2584-602. PubMed ID: 25450340
[TBL] [Abstract][Full Text] [Related]
2. P2X7 receptor antagonism in the treatment of cancers.
Roger S; Pelegrin P
Expert Opin Investig Drugs; 2011 Jul; 20(7):875-80. PubMed ID: 21619470
[TBL] [Abstract][Full Text] [Related]
3. P2X7 receptor: a critical regulator and potential target for breast cancer.
Zhu X; Li Q; Song W; Peng X; Zhao R
J Mol Med (Berl); 2021 Mar; 99(3):349-358. PubMed ID: 33486566
[TBL] [Abstract][Full Text] [Related]
4. Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells.
Di Virgilio F; Jiang LH; Roger S; Falzoni S; Sarti AC; Vultaggio-Poma V; Chiozzi P; Adinolfi E
Methods Enzymol; 2019; 629():115-150. PubMed ID: 31727237
[TBL] [Abstract][Full Text] [Related]
5. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties.
Zhang WJ; Hu CG; Zhu ZM; Luo HL
Biomed Pharmacother; 2020 May; 125():109844. PubMed ID: 32004973
[TBL] [Abstract][Full Text] [Related]
6. Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
Scarpellino G; Genova T; Munaron L
Recent Pat Anticancer Drug Discov; 2019; 14(1):32-38. PubMed ID: 30652649
[TBL] [Abstract][Full Text] [Related]
7. P2X7 Receptor as a Therapeutic Target.
De Marchi E; Orioli E; Dal Ben D; Adinolfi E
Adv Protein Chem Struct Biol; 2016; 104():39-79. PubMed ID: 27038372
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
[TBL] [Abstract][Full Text] [Related]
9. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.
Drill M; Jones NC; Hunn M; O'Brien TJ; Monif M
Purinergic Signal; 2021 Jun; 17(2):215-227. PubMed ID: 33728582
[TBL] [Abstract][Full Text] [Related]
11. ATP in the tumour microenvironment drives expression of nfP2X
Gilbert SM; Oliphant CJ; Hassan S; Peille AL; Bronsert P; Falzoni S; Di Virgilio F; McNulty S; Lara R
Oncogene; 2019 Jan; 38(2):194-208. PubMed ID: 30087439
[TBL] [Abstract][Full Text] [Related]
12. Functional Coupling between the P2X
Inoue H; Kuroda H; Ofusa W; Oyama S; Kimura M; Ichinohe T; Shibukawa Y
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205953
[TBL] [Abstract][Full Text] [Related]
13. How is the P2X7 receptor signaling pathway involved in epileptogenesis?
Wei C; Fu M; Zhang H; Yao B
Neurochem Int; 2024 Feb; 173():105675. PubMed ID: 38211839
[TBL] [Abstract][Full Text] [Related]
14. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.
Baudelet D; Lipka E; Millet R; Ghinet A
Curr Med Chem; 2015; 22(6):713-29. PubMed ID: 25515510
[TBL] [Abstract][Full Text] [Related]
16. [Advance in the research on P2X7 and inflammatory respiratory diseases].
Cao SH; Yuan SP; Hou Q
Yao Xue Xue Bao; 2013 Aug; 48(8):1183-8. PubMed ID: 24187823
[TBL] [Abstract][Full Text] [Related]
17. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
[TBL] [Abstract][Full Text] [Related]
18. A novel role for P2X7 receptor signalling in the survival of mouse embryonic stem cells.
Thompson BA; Storm MP; Hewinson J; Hogg S; Welham MJ; MacKenzie AB
Cell Signal; 2012 Mar; 24(3):770-8. PubMed ID: 22120528
[TBL] [Abstract][Full Text] [Related]
19. Lidocaine preferentially inhibits the function of purinergic P2X7 receptors expressed in Xenopus oocytes.
Okura D; Horishita T; Ueno S; Yanagihara N; Sudo Y; Uezono Y; Minami T; Kawasaki T; Sata T
Anesth Analg; 2015 Mar; 120(3):597-605. PubMed ID: 25695577
[TBL] [Abstract][Full Text] [Related]
20. P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases.
Mishra A; Behura A; Kumar A; Naik L; Swain A; Das M; Sarangi SS; Dokania P; Dirisala VR; Bhutia SK; Mishra A; Singh R; Dhiman R
Eur J Pharmacol; 2021 Sep; 906():174235. PubMed ID: 34097884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
